EuroPCR 2018: Robocath Eyes December CE Mark For R-One Positive Pre-Clin Data
Executive Summary
Robocath is planning a year-end market launch of its flagship R-One robotic catheterization system after the preclinical trial of R-One hit all primary endpoints. If the product is CE-marked in December as anticipated, it will be a rival to Corindus Vascular's CorPath, which is currently the only robotic-assisted system in the market for interventional cardiology. Robocath announced the preclinical data at EuroPCR in Paris, being held this week until May 25.
You may also be interested in...
Robocath Updates Progress With R-One Robotic Coronary Intervention Platform
French company Robocath believes its R-One robotic catheter intervention system will make coronary interventions more efficient for hospitals and safer for interventionalists. Robocath is sponsoring a 60-patient European trial of coronary interventions with R-One.
Global Device Approvals Q2 Shapshot: Coronary Devices Abound
The second quarter of 2018 brought 62 approvals from outside the US, including 46 in Europe, according to Medtech Insight's Approvals Tracker. Among those approvals, 14 were for devices to treat coronary artery disease, and the second most-common indications were obesity and soft-tissue repair. Outside of Europe, Japan had the most non-US approvals in the quarter with five.
EuroPCR 2017: Robocath Eyes H1 2018 Robotic Catheterization System Launch With New Funds
Emerging medical robotics firm Robocath has raised fresh funds to take its R-one system through clinical trials and into the market by the first half of next year.